Sleep plays a pivotal role in good health and well-being throughout life, and yet for millions of Americans sleep is regularly interrupted or insufficient. To address the multiple needs of this growing population, NewYork-Presbyterian/Weill Cornell established the Weill Cornell Center for Sleep Medicine.

Neuroendovascular surgery has undergone a rapid evolution since it first emerged as a specialty, with neuroendovascular therapies for the treatment of both ischemic stroke and intracranial aneurysms showing great promise for improved diagnosis and clinical outcomes.

From the genome to the microbiome and several omics in between, data are being generated that can provide significant biological insights into the disease.

Researchers have developed a quantitative MRI measure that reflects the joint contributions of neurodegeneration, brain infarcts, and white matter hyperintensities (WMH) to the clinical and pathologic diagnosis of late onset Alzheimer’s disease (LOAD).

Researchers at Weill Cornell Medicine have shown that measuring brain activity in response to hearing a brief narrative can identify patients with severe brain injury who have preserved high-level cognition despite showing limited or no consciousness at the bedside.

In a study published in journal Nature Communications, researchers at Weill Cornell Medicine identify a protein that increases the risk of cognitive impairment.

With this formal appointment, Dr. Cigdem Akman continues the exceptional leadership she has demonstrated over the past year in driving the overall expansion of the division’s clinical, research, and education programs.

The brain and spine tumor programs at NewYork-Presbyterian integrate multiple disciplines to provide comprehensive treatment strategies that include minimally invasive surgery, radiation therapies, and intra-arterial chemotherapy.